Long-Term Daily Oral PrEP With FTC/TAF Is Effective, Well Tolerated For HIV Prevention, Research Suggests

Infectious Disease Advisor (9/4, Nye) reports research found that “long-term daily oral pre-exposure prophylaxis (PrEP) with emtricitabine (FTC) plus tenofovir alafenamide (TAF) was found to be effective and well tolerated for HIV prevention, with treatment adherence observed through 144 weeks.” In a “safety analysis of patients who received up to 144 weeks of FTC/TAF, 94% reported treatment-emergent adverse event[s] (AEs), 3% experienced grade 3 or 4 treatment-emergent AEs, and less than 1% experienced severe study drug-related AEs.” The findings were published in The Lancet HIV.